Elizabeth Jungman

Elizabeth Jungman

  • Director
  • Public Health,
  • The Pew Charitable Trusts


Elizabeth Jungman directs Pew’s work on public health, overseeing initiatives related to antibiotics and innovation, drug safety, and prescription drug abuse.

Before joining Pew, she served as a senior health policy adviser with the U.S. Senate Committee on Health, Education, Labor, and Pensions, where she played a key role in drafting and negotiating the Food and Drug Administration Safety and Innovation Act of 2012, the FDA provisions in the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013, and the Drug Quality and Security Act of 2013, which included drug compounding and supply chain security measures.

Before moving to the Hill, Jungman was in private legal practice, counseling clients on a broad range of FDA regulatory matters and other health care issues related to the human pharmaceutical industry. She serves on FDA’s Pharmacy Compounding Advisory Committee and represents Pew as a member of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria. She has an undergraduate biology degree from Harvard College, a Juris Doctor from Georgetown University, and a master’s degree in public health from Johns Hopkins University.

Recent Work

View All
  • Why Drug Compounding Is Not a Solution to High Prices

    Recent spikes in the price of certain off-patent medications have caused some legislators and health care professionals to advocate for using compounded drugs—drugs mixed by pharmacies—as a substitute for more expensive, FDA-approved medications. Though well-intentioned, this approach carries significant risks for patients and the sustainability of the drug approval system for the... Read More

  • Pew Continues to Urge Congress to Ensure Patient Safety

    As the debate over drug pricing persists on Capitol Hill, The Pew Charitable Trusts’ drug safety project is working to educate members of Congress about the dangers of allowing compounded drugs—drugs made by pharmacists—to serve as a low-cost alternative to FDA-approved medications. In advance of the U.S. House of Representatives’ Feb. 4 Oversight and Government Reform Committee hearing... Read More

  • Pew Urges Senate HELP Committee to Maintain Drug Safety Standards

    In advance of the Jan. 28 hearing, “Generic Drug User Fee Amendments: Accelerating Patient Access to Generic Drugs,” Allan Coukell, senior director of health programs at The Pew Charitable Trusts, sent a letter to members of the U.S. Senate Committee on Health, Education, Labor, and Pensions. In the letter, Coukell highlights the risks of relying on compounded drugs—medicines made by... Read More

Media Contact

Linda Paris

Manager, Communications, Medical Programs